News | Peripheral Artery Disease (PAD) | August 28, 2015

First Pennsylvania Patient Treated With BioMimics 3D Vascular Stent in Landmark Study

PinnacleHealth CardioVascular Institute offers new treatment option for leg artery blockages

biomimics, 3D stent

August 28, 2015 — PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania and second in the United States in a trial assessing the safety and effectiveness of a new type of stent for blockages in the femoral artery. The new stent allows for greater flexibility within the artery and potentially less risk for stent fracture or re-narrowing after the stent is placed.

The MIMICS-2 trial is a prospective, single-arm, multicenter clinical trial of the BioMimics 3D stent system and will enroll 280 subjects in up to 40 sites in the United States and Germany. William Bachinsky, M.D., FACC, medical director of vascular services at PinnacleHealth CardioVascular Institute, serves as principal investigator locally at PinnacleHealth.

The BioMimics 3D nitinol stent has unique helical curvature that involves adapting a straight stent design to a three-dimensional helical shape, which more closely mimics the natural geometry of the human vascular system.

"We are very excited about having this cutting edge technology available only at PinnacleHealth for patients with claudication or pain in the legs due to leg artery blockages," said Bachinsky. "The BioMimics 3D Stent could be a game changer in femoral artery stent technology that may make the stents remain effective longer for patients."

The MIMICS-2 Study is one of more than 50 clinical trials for cardiovascular care currently underway at PinnacleHealth. 

For more information: www.pinnaclehealth.org

Related Content

Philips Showcases Integrated Solutions for Cardiovascular Care at TCT 2018
News | Cath Lab | September 20, 2018
At the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, Sept. 21–25 in San Diego, Philips is showcasing...
Sponsored Content | Videos | Cath Lab | September 19, 2018
William O’Neill, M.D., outlines his recent clinical publication of AMICS patients from the Impella Quality (IQ) datab
Videos | Cath Lab | September 14, 2018
A discussion with Nicolas Bevins, Ph.D., vice chair, physics and research, and Jessica Harrington, RCIS.
A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. DAIC staff photo by Dave Fornell

A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. (right) who is proctoring a fellow in treating CTOs.

Feature | Cath Lab | September 13, 2018 | Artur Kim, Kamran Zamanian
Coronary artery disease (CAD) is a multifaceted disease that demands various approaches in terms of diagnosis and tre
Videos | Cath Lab | August 13, 2018
Jeffrey Schussler, M.D., FACC, FSCAI, FSCCT, FACP, interventional cardiologist at Baylor Scott White Heart and Vascul
Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
FFR software on the GE Centricity CVIS. A trial from the 2018 EuroPCR meeting showed FFR improves long-term outcomes.
News | Cath Lab | May 29, 2018
May 29, 2018 — Ongoing controversy exists regarding the role of percutaneous coronary intervention (PCI) for stable c
SCAI Updates Consensus on Length of Stay for Percutaneous Coronary Intervention
News | Cath Lab | May 15, 2018
Revised guidelines incorporating new data on discharge criteria for patients undergoing elective percutaneous coronary...
No Benefit Found Using Sodium Bicarbonate, Acetylcysteine to Prevent Kidney Injury, the result of the PRESERVE Trial to prevent acute kidney injury (AKI), presented at SCAI 2018.  #SCAI, #SCAI2018,
Feature | Cath Lab | May 15, 2018
May 15, 2018 – The large-scale, international randomized PRESERVE clinical trial found high-risk patients for renal c
Angiogram of a STEMI patient.
News | Cath Lab | May 15, 2018
May 15, 2018 — A contemporary, real-world analysis shows lower mortality rates when culprit-only intervention is used
Overlay Init